0000000000297019

AUTHOR

Liga Kuksa

showing 2 related works from this author

Use of delamanid for M/XDR-TB treatment under programmatic conditions in Latvia

2016

Introduction. Since 2014 Delamanid (Dlm) was introduced in M/XDR-TB treatment under programmatic conditions. The aim of this study was to analyse experience of Dlm use. Methods. For all MDR-TB cases treatment regimens (Tx) are designed by MDR-TB expert committee. Dlm is prescribed for patients with risk of failure of Tx due to resistance or severe intolerance of key 2 nd line drugs. We analysed clinical and demographic data for all patients who received Dlm during the period of July 2014 to February 2016. Data were collected from patient9s medical records. Results. In total 20 MDR TB patients received Dlm: 3 female and 17 male with median age 46 years, including 2 children (11 and 13 years …

Pediatricsmedicine.medical_specialtybusiness.industryMedical recordPyrazinamidechemistry.chemical_compoundchemistryLevofloxacinMoxifloxacinLinezolidMedicineLost to follow-upDelamanidbusinessAdverse effectmedicine.drug10.2 Tuberculosis
researchProduct

Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia

2016

This test decreased time to treatment initiation by 66%–84%.

0301 basic medicineOncologyMaleEpidemiologylcsh:Medicine0302 clinical medicine1108 Medical MicrobiologyTuberculosis Multidrug-Resistant030212 general & internal medicinebacteriaDecreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test Latviabiologytime to treatment initiationDrug Resistance MicrobialMiddle Agedmultidrug-resistant tuberculosisRifampin resistanceInfectious Diseases1117 Public Health And Health ServicesTuberculosis Multidrug-Resistant/diagnosisFemaleRifampinLife Sciences & BiomedicineMicrobiology (medical)Adultmedicine.medical_specialtyTuberculosisAdolescentpulmonary030106 microbiologyXpert MTB/RIFImmunologyTime to treatmentMicrobiologylcsh:Infectious and parasitic diseasesTime-to-TreatmentMycobacterium tuberculosismolecular diagnostics03 medical and health sciencesYoung AdultAntibiotic resistancemultidrug resistanceInternal medicinemedicineHumanslcsh:RC109-216Multivariable modelantimicrobial resistanceTuberculin testAntibiotics AntitubercularScience & Technologybusiness.industryTuberculin TestResearchlcsh:RMycobacterium tuberculosis/drug effects1103 Clinical SciencesMycobacterium tuberculosisbiology.organism_classificationmedicine.diseaseAntibiotics Antitubercular/pharmacologyLatviatuberculosis and other mycobacteriaMultiple drug resistanceMODELTuberculin Test/methodsbusinessRifampin/pharmacologyMDR TB
researchProduct